Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
Background: Fluoropyrimidine toxicity is often due to variations in the gene (DPYD) encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to adjust doses to reduce the likelihood of fluoropyrimidine toxicity while maintaining therapeutically effective drug levels.Methods: A mul...
Saved in:
Main Authors: | Angela Wu (Author), Helen Anderson (Author), Curtis Hughesman (Author), Sean Young (Author), Caroline Lohrisch (Author), Colin J. D. Ross (Author), Bruce C. Carleton (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
by: Georgia Ragia, et al.
Published: (2023) -
Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
by: Ursina B. M. Begré, et al.
Published: (2022) -
Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review
by: Zulfan Zazuli, et al.
Published: (2018) -
Challenges in DPYD Test Implementation in Patients Treated with Fluoropyrimidines are DPYD Genotype Arriving on Time? [Letter]
by: López López-Cepero M, et al.
Published: (2023) -
DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol
by: Ana Hernández-Guío, et al.
Published: (2021)